Gastroenteritis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Gastroenteritis – Pipeline Review, H2 2016’, provides an overview of the Gastroenteritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastroenteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastroenteritis

The report reviews pipeline therapeutics for Gastroenteritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gastroenteritis therapeutics and enlists all their major and minor projects

The report assesses Gastroenteritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gastroenteritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gastroenteritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Nanotherapeutics, Inc.

RedHill Biopharma Ltd.

Takeda Pharmaceutical Company Limited

UMN Pharma Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gastroenteritis Overview 6

Therapeutics Development 7

Pipeline Products for Gastroenteritis - Overview 7

Pipeline Products for Gastroenteritis - Comparative Analysis 8

Gastroenteritis - Therapeutics under Development by Companies 9

Gastroenteritis - Therapeutics under Investigation by Universities/Institutes 10

Gastroenteritis - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Gastroenteritis - Products under Development by Companies 14

Gastroenteritis - Products under Investigation by Universities/Institutes 15

Gastroenteritis - Companies Involved in Therapeutics Development 16

Nanotherapeutics, Inc. 16

RedHill Biopharma Ltd. 17

Takeda Pharmaceutical Company Limited 18

UMN Pharma Inc. 19

Gastroenteritis - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

Antibodies for Gastroenteritis - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

norovirus (bivalent) virus like particle vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

ondansetron hydrochloride CR - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

TAK-214 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

UMN-2002 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

UMN-2003 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Gastroenteritis - Product Development Milestones 39

Featured News & Press Releases 39

Jun 20, 2016: Takeda Initiates Worlds First Norovirus Vaccine Field Trial 39

Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102 39

Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D 40

Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 41

Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 42

Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 43

Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis 44

Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness 45

Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development for Gastroenteritis, H2 2016 7

Number of Products under Development for Gastroenteritis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Gastroenteritis – Pipeline by Nanotherapeutics, Inc., H2 2016 16

Gastroenteritis – Pipeline by RedHill Biopharma Ltd., H2 2016 17

Gastroenteritis – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 18

Gastroenteritis – Pipeline by UMN Pharma Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

List of Figures

List of Figures

Number of Products under Development for Gastroenteritis, H2 2016 7

Number of Products under Development for Gastroenteritis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports